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Hormonal Regulation of Cytosolic Free
Calcium and Its Functional Consequences:
The GH-Cell Model
by Armen H. Tashjian, Jr.*
Use of clonal strains of prolactin (PRL)- and growth hormone-producing rat pituitary cells has
proven informative in elucidating a number of the early biochemical, ionic, and secretory events
regulated by the hypothalamic tripeptide, thyrotropin-releasing hormone (TRH). TRH causes
biphasic changes in the concentration ofcytosolic free calcium([Ca2"J,) in GH4C1 cells and biphasic
changes in hormone secretion. Early changes occur on a msecond to second scale and late changes,
on a time scale of minutes. Although increases in [Ca2"], are essential for enhanced secretion, at
least in the case ofthe rapid initial phase, the TRH-induced increase in [Ca2], is necessary, but not
sufficient to enhance secretion. A co-mediator with calcium appears to be diacylglycerol.
The majority of the calcium involved in the early phase of rise in [Ca21J] induced by TRH is
derived from intracellular sources, while essentially all of the calcium rise observed in the late
phase is derived from extracellular calcium entering the cell through both voltage-dependent and
voltage-independent conductances. Because TRH causes an elevation of inositol(1,4,5)
trisphosphate [Ins(1,4,5)P3] within seconds, but not mseconds, further studies are required before
it can be concluded unequivocally that Ins(1,4,5)P3 is the sole mediator of the rapid phase of rise
in [Ca2"], induced by TRH in GH-cells. Additional experiments with GH4C1 cells have revealed that:
a) maximal ligand-stimulated activation of protein kinase C requires a rise in [Ca2+J1 as well as
diacylglycerol; b) the rapid action of TRH on [Ca2+1i is potentiated by 1,25(OH)2-cholecalciferol by
a mechanism that involves enhanced entry of extracellular calcium; c) TRH regulates the Na+/H+
exchanger in GH-cells to cause cytosolic alkalinization; and finally, d) we have recently solubi-
lized the TRH receptor from GH4CI cells in a functionally active form that is coupled to its guanine
nucleotide-binding and transducing protein.
Introduction
This paper summarizes the results of experiments
performed in my own laboratory on the regulation of
cytosolic free calcium [Ca2+]i and prolactin (PRL)
secretion by thyrotropin-releasing hormone (TRH).
The model we have investigated extensively uses the
so-called GH-cell system, particularly GH4C1 and GH3
cells (1-3). These cells have been used extensively in
many laboratories worldwide to study the regulation
of the expression of the growth hormone and PRL
genes, the mechanisms of action of vasoactive intesti-
nal peptide, somatostatin, epidermal growth factor,
platelet-derived growth factor, bombesin, thyroid
hormones, glucocorticoids, estradiol, and 1,25(OH)2-
cholecalciferol (1,25(OH)2D3) as well as the phorbol
ester tumor promoters. Furthermore, a number of
studies have used electrophysiological methods to
characterize ion channels and cation conductances
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across the plasma membrane of these cells. In this
synopsis I shall not cite any of the many and impor-
tant contributions from other investigators.
I have chosen to discuss several specific aspects of
the roles of [Ca2+]i and inositol phospholipids in hor-
mone-receptor signaling pathways in GH-cells. A
number of generalities can be derived from this cell
system, but it is not representative of all protein-
secreting cells that use inositol lipids and their
hydrolysis products for intracellular signaling. This
conclusion does not, however, limit the usefulness of
GH-cells but indicates that other models need to be
studied in comparable detail.
Early Actions of TRH on Cytosolic
Free Calcium
The actions of TRH on GH4C1 cells mediated via its
specific plasma membrane receptor (4-6) that occur
over a time span of several hundred mseconds to sev-
eral minutes include the following: a) increases in
[Ca2+]i that are biphasic, b) enhanced inositol lipidA. H. TASHJIAN, JR.
hydrolysis, c) release of cell calcium into the extracel-
lular environment, d) influx of extracellular calcium,
e) enhanced number of calcium-dependent action
potentials, ) activation of protein kinase C and other
protein kinases, g) altered pattern of protein phos-
phorylation, h) increased intracellular pH (pHi), and
i) release of stored, previously synthesized PRL that
is biphasic.
Three major experimental approaches have been
used to examine the early actions of TRH. These are
electrophysiological studies, 'Ca2" flux analyses, and
biochemical investigations of phospholipid turn-
over and protein phosphorylation. Most investigators
agree that a rise in [Ca2+]i is essential to trigger the
PRL release enhanced by TRH; however, there have
been uncertainties or differences between laborato-
ries regarding the source or sources of the calcium
that contribute to the increase in [Ca2+]i. I shall
describe the results of a series of experiments per-
formed largely by Paul Albert, a graduate student in
my laboratory, which, coupled with earlier results of
Kut-Nie Tan, have lead us to conclude that both the
redistribution of intracellular calcium and entry of
extracellular calcium play important roles in the
biphasic pattern of PRL secretion that is elicited by
TRH.
Using Quin-2 to monitor [Ca2+]i, we have identified
two phases of change in [Ca2+]i induced by TRH (7).
An acute spike occurs rapidly and decays with a half-
time of about 7.5 sec toward the baseline [Ca2+]i.
Within about 300 msec after addition of TRH, there is
a highly significant increase in [Ca2+]i that peaks at 1
to 2 sec (8). After the decay of the spike phase, a
secondary rise in [Ca2+]i occurs that reaches a new
plateau value for [Ca2+]i within about 3 min. This sec-
ondary plateau is persistent for many minutes in the
continued presence of TRH. Thus, the changes in
[Ca2+]i induced by TRH are biphasic.
For the burst phase of increase in [Ca21]i, the
majority (about 80%) is derived from intracellular
calcium stores (8). However, the plateau phase of rise
in[Ca2+]i is eliminated by the removal of extracellular
calcium (8).
Relationship between the Biphasic
Changes in [Ca2+]i and Prolactin
Secretion
Changes in [Ca2+]i and PRL release were monitored
simultaneously in Quin-2-loaded GH4C1 cells. After
addition of TRH, there is a biphasic change in PRL
secretion (8,9). An initial burst of PRL release occurs
within the first 1 to 2 min, which is reflected in a 10-
to 20-fold increase in the interval rate of secretion.
Thereafter, the rate of TRH-enhanced secretion falls
to a new sustained rate that is 2- to 3-fold above the
control rate. Temporal analysis of changes in [Ca2+]i
and secretion indicates that the spike phase of
increase in [Ca2+]i precedes the burst phase of
increased PRL release by 10 to 20 sec and that the
plateau phase of [Ca2+]i and sustained PRL secretion
occur essentially simultaneously (8,9).
To dissect the causative interrelationship between
the two phases of TRH action on [Ca2+]i and secretion,
we searched for selective blockers of the burst and
plateau phases and found that ionomycin could selec-
tively block the burst phases and that the voltage-
gated calcium channel antagonists (nifedipine and
verapamil) could depress basal [Ca2+]i and the plateau
phases of the [Ca2+]i rise and secretion without alter-
ing the TRH-induced spike phases. Low concentra-
tions of ionomycin (10-100 nM) cause a spike in[Ca2]i
in GH4C1 cells that resembles closely the spike pro-
duced by TRH (8,10). To test whether a redistribution
of cellular calcium or influx of extracellular calcium
was responsible, we pretreated cells with EGTA
before adding ionomycyn. The conditions we used
blocked completely K+-induced influx of extracellular
calcium. Chelation of extracellular calcium with
EGTA did not prevent the spike in [Ca2+]i induced by
ionomycin. Therefore, the burst in [Ca21]i caused by
ionomycin is due to release of intracellular calcium.
This pattern ofchange in[Ca2+]iinduced by ionomycin
in the presence of EGTA was very similar to the pat-
tern of change in [Ca2+]i induced by TRH under the
same conditions (8).
The similarities of the pattern induced by TRH and
ionomycin suggested that both agents might be acting
on the same cellular calcium reservoir. Therefore, we
determined whether or not TRH could cause a spike
in [Ca2+]i if the peptide were added to cells after iono-
mycin. TRH did not induce a spike in [Ca2+]i if it was
added 5 min after ionomycin (8); however, the TRH-
induced plateau phase of increase in [Ca2+]i induced by
TRH was fully intact after ionomycin pretreatment.
Therefore, the TRH-induced plateau in [Ca2+]i is not
dependent on a prior TRH-induced spike in[Ca2+]j. We
interpret these results to indicate that ionomycin and
TRH act on the same intracellular pool of calcium,
and prior treatment with ionomycin depletes that
pool rendering it unavailable to the action of TRH.
Having identified the effects of ionomycin on
[Ca2]i, we then examined its actions on basal and
TRH-stimulated PRL secretion. Ionomycin alone,
despite causing a spike in [Ca2+], did not cause a burst
in the secretion of PRL (8). Therefore, the spike in
[Ca2+]i alone is not sufficient to cause a burst of secre-
tion. If ionomycin was added to the cells 5 min before
TRH, the TRH-induced spike in [Ca2+]i was blocked,
and the TRH-induced burst of PRL secretion was also
blocked completely (8). Ionomycin did not block the
TRH-induced plateau phase of enhanced secretion.
Therefore, a spike in [Ca2+]i is needed for the burst
phase of secretion induced by TRH, but the spike in
[Ca2+]i alone is not sufficient.
We have performed analogous experiments with
calcium channel antagonists that block voltage-
dependent calcium channels in GH4C1 cells (8).
Nifedipine and verapamil block that component of the
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TRH-induced plateau phases of [Ca2+]i and enhanced
secretion that are due to calcium entry via voltage-
dependent calcium channels (about 60% of extracellu-
lar calcium enters through these channels); however,
nifedipine or verapamil do not block the TRH-induced
spike in [Ca2+]i or the bust in PRL secretion.
Based on knowledge from other laboratories that
TRH activates phospholipase C via its receptor and a
G-protein, we consider it likely that diacylglycerol
(DAG) acts as a co-mediator with calcium in the
burst phase of PRL secretion. This conclusion is sup-
ported by the results of two kinds of experiments.
First, we reconstituted the precise TRH-induced pat-
tern of change in both [Ca2+]i and PRL secretion using
ionomycin to cause the spike in [Ca2+]i plus the
phorbol ester 12-O-tetradecanoylphorbol-13-acetate
(TPA) to mimic the action of endogenous DAG (9).
When secretion was examined, the TRH-induced pat-
tern was also reproduced, essentially identically, by
the combination of ionomycin and TPA (9). The sec-
ond line of evidence implicating endogenous DAG in
the acute secretory action of TRH came from experi-
ments examining the rapid activation of protein kin-
ase C by TRH (11). We measured activation of protein
kinase C by determining its subcellular localization at
early times after treating GH4C1 cells with TRH (11).
There was a rapid (< 10 sec) loss of protein kinase C
activity or phorbol ester binding from the cytosol and
also an equally rapid increase in protein kinase C in
the particulate membrane fraction of the cell. Thus, it
was possible to mimic TRH actions on [Ca2+]i and
secretion with ionomycin plus TPA and demonstrate
that TRH activates rapidly protein kinase C, an
important intracellular target for the action of endog-
enous DAG.
Is lns(1,4,5)P3 the Sole Mediator of
Intracellular Calcium Redistribution in
GH-Cells?
Results from several other investigators have
shown that TRH activates phospholipase C and
causes generation of Ins(1,4,5)P3 in GH-cells within 2
to 5 sec. Ins(1,4,5)P3 also causes calcium release from
sequestered stores when added to permeabilized GH-
cells. However, as indicated above, TRH causes an
elevation of [Ca2+]i in GH-cells within 300 msec (8). If
Ins(1,4,5)P3 that is generated in response to TRH is
the intracellular mediator of TRH action on [Ca2+]j, it
would be expected that enhanced Ins(1,4,5)P3 forma-
tion would occur as rapidly, if not more rapidly, than
the increase in [Ca2+]i induced by TRH. When we
examined the kinetics of Ins(1,4,5)P3 in detail in
GH4C1 cells, we found a lag of 1000 to 1200 msec
before the increase in Ins(1,4,5)P3 could be detected,
while the rise in [Ca2+]i occurred within about 300
msec (12). This result was not due to our inability to
measure rapid changes in inositol polyphosphates,
because we could measure changes in InsP4 and InsP5
between 400 and 1000 msec (12,13). These findings
suggest that the current dogma that Ins(1,4,5)P3 is
the sole mediator of intracellular calcium redistribu-
tion in GH-cells may need to be reconsidered.
Additional Aspects of Signal
Transduction in GH-CelIs
In the course of further studies with ionomycin,
C.W. Fearon noted that low concentrations of the
ionophore itself did not cause redistribution of pro-
tein kinase C, but that pretreatment with ionomycin
antagonized the action of TRH (14). The antagonism
required pretreatment for greater than 10 sec and
was reversed by high K+ in the presence of extracellu-
lar calcium. These results lead us to conclude that
optimal activation of protein kinase C by TRH
requires a simultaneous rise in both DAG and [Ca2]i
(14).
GH4C1 cells were loaded with Quin 2 and the fluo-
rescent proton reporter bis(carboxyethyl)carboxy-flu-
orescein (BCECF) and TRH-induced changes in pHi
monitored (15). In acid loaded cells, TRH causes a
rapid increase in pHi that is independent of changes
in [Ca2+]i and is blocked by amiloride. Thus, TRH
stimulates the activity in the Na+/H+ antiporter in
GH-cells. The mechanism appears to involve activa-
tion of protein kinase C, but this may not be the sole
mode of control of pHi by TRH.
The acute action of TRH on [Ca2+]i is modulated in
GH4C1 cells by 1,25(OH)2D3. It has been shown that
1,25(OH)2D3 causes an increase in PRL synthesis and
PRL mRNA accumulation in GH4Ci cells in a calcium-
dependent manner (16,17). 1,25(OH)2D3 does not cause
rapid (minutes) changes in [Ca2+]j. However, pretreat-
ment of cells depleted of vitamin D with 1,25(OH)2D3
(10-10 M) for 24 to 48 hr causes a 2-fold enhancement
of the TRH-induced spike in [Ca21]i with no change in
the TRH-induced plateau phase of change in [Ca21]i
(18). The mechanism does not involve a change in
TRH receptors, in inositol phosphate generation and
in protein kinase C activity, or an increase in the
intracellular reservoir of calcium on which TRH acts.
Because acute removal of extracellular calcium blocks
the 1,25(OH)2D3 effect, the action of vitamin D
appears to be mediated by enhanced influx of
extracellular calcium induced by TRH (18). The TRH-
regulated influx channel or pathway regulated by
1,25(OH)2D3 has not yet been identified.
Finally, we have solubilized the TRH receptor from
GH-cells using 1% digitonin (19). Solubilization of
the unoccupied receptor gives a soluble receptor that
preserves the binding characteristics of the mem-
brane or whole cell receptor including competition for
TRH binding by chlordiazepoxide. Solubilization of
the TRH-occupied receptor gives a soluble and func-
tional TRH-receptor-G protein complex.
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Conclusion
GH-cells have proven useful in identifying and
characterizing a variety of important receptor-medi-
ated transduction and regulatory pathways in protein
hormone secreting cells. Although much has been
learned, much more remains to be discovered using
this novel cell culture system.
The experiments described in this resume were performed under
support, in part, by a research grant from NIH (DK 11011). The
author thanks Jean Foley for her expert help in preparing this
manuscript.
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